What Pneuma Respiratory does

Pneuma Respiratory, Inc. is a private MedTech company headquartered in Boone, North Carolina, developing advanced aerosol generation technology for pulmonary drug delivery. Its core competency is precision aerosol physics — producing droplets as small as 600 nanometers with up to 90% respirable fraction — combined with low-shear generation that preserves fragile biologics, propellant-free breath-actuated dosing, and digitally enabled features (voice guidance, dose verification, Bluetooth connectivity, cloud-based adherence reporting). The platform is protected by 57 issued patents and 135+ pending applications covering aerosol generation methods, biologic compatibility, breath-actuation, dose tracking, voice coaching, multi-formulation compatibility, and adherence analytics.

The company operates two product lines on a single technology platform: a Pharmaceutical Delivery Platform (branded Enhaler) targeting asthma, COPD, oncology (including non-small cell lung cancer), and emerging inhaled biologic programs, commercialized via licensing and co-development with pharmaceutical partners; and a Reduced-Risk Nicotine Delivery Platform targeting adult smokers and the nicotine harm-reduction market through a direct-to-consumer hardware model with companion app integration. Manufacturing is anchored by a Foxconn-led operation in Shenzhen, China, with regional leadership in place for Pneuma Asia and China Operations.

Pneuma has raised approximately $29.6M across multiple rounds from 2018 through mid-2025, including a Series E from Marble City Angels and Music City Angels operating under the Community Equity Partners network. The company remains pre-commercial — no revenue is disclosed, no named customer logos appear, and both product platforms are progressing toward clinical trials and consumer launch — while operating with a leadership team that includes the co-founder of Cree Inc. (now Wolfspeed), a Fulbright Scholar/NASA Faculty Fellow in aerosol physics, and a retired global tobacco company CEO.

Name

Pneuma Respiratory

Legal name

Pneuma Respiratory, Inc.

Website

https://pneumarespiratory.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Pneuma Respiratory is a private MedTech company developing advanced aerosol generation technology for precise pulmonary drug delivery, targeting pharmaceutical partners in respiratory and oncology therapeutics and consumers through a reduced-risk nicotine delivery platform.

Ownership category

akta.pro rank

Product category

Inhaled Drug Delivery

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Inhalers (MDI/DPI/SMI) (HLAHAIAI)

akta.pro secondary industries

Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Inhaled drug delivery
• Smart inhaler technology
• Aerosol generation systems
• Pulmonary therapeutics platform
• Smoking cessation devices

Headquarters

HQ city

Boone

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Consumer Nicotine/Harm Reduction Device Sales: Revenue from sale of non-heated nicotine delivery devices targeting smoking cessation and nicotine harm reduction. The fully digital design enables companion app integration, dose control, and customization.
2. Pharmaceutical Therapeutic Delivery Platform: Revenue from pharmaceutical delivery platform licensing or co-development for small molecules and biologics across asthma, COPD, oncology, and emerging therapeutic areas. Broad formulation compatibility enables partnership with pharmaceutical companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Pneuma Respiratory develops advanced aerosol generation technology for pulmonary drug delivery, producing ultra-fine droplets as small as 600 nanometers with up to 90% respirable fraction. Its flagship Enhaler smart inhaler device enables breath-actuated, propellant-free dosing of small molecules and large-molecule biologics, supporting both a Reduced-Risk Nicotine Delivery Platform for consumer smoking cessation and a Pharmaceutical Delivery Platform for inhaled therapeutics in asthma, COPD, and oncology. The platform is paired with digital features including voice guidance, dose verification, Bluetooth connectivity, and cloud-based adherence reporting.

Product overview

Pneuma Respiratory offers two distinct platforms built on a single breakthrough aerosol generation technology: the Reduced-Risk Nicotine Delivery Platform targeting smoking cessation and harm reduction, and the Pharmaceutical Delivery Platform for inhaled therapeutics. Both platforms are delivered through the Enhaler device, which features ultra-fine droplet generation (as small as 600 nanometers), up to 90% respirable fraction, breath-actuated propellant-free dosing, and digitally enabled features including voice guidance, dose verification, and Bluetooth connectivity for adherence monitoring.

Differentiator

Problem solved

Functional benefit

Brands

• Enhaler: Pharmaceutical delivery platform for precise pulmonary drug delivery
• Reduced-Risk Nicotine Delivery Platform

Products and services

• Enhaler Smart Inhaler Device

Quantifiable outcome

• Up to 90% respirable fraction/lung deposition
• +2 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Foxconn (Hon Hai Precision Industry)coreOEM/ Whitelabel/ Licensing PartnerFoxconn serves as the lead manufacturer for Pneuma Respiratory's products, providing high-volume manufacturing capabilities and supply chain expertise. This manufacturing partnership enables Pneuma to scale production of its aerosol generation devices.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Aerami Therapeutics: Aerami Therapeutics develops inhaled drug delivery for serious respiratory diseases such as pulmonary hypertension, using a proprietary nebulizer platform. It is a direct peer to Pneuma's pharmaceutical delivery platform, competing on the same biologic-friendly, breath-actuated nebulization/inhaler technology axis.
• Respira Technologies: Respira Technologies builds proprietary aerosol platforms for inhaled therapeutics, including cannabinoid and respiratory drug delivery. Comparable to Pneuma in targeting next-generation inhaler/nebulizer platforms with broad formulation compatibility.
• Insmed: Insmed commercializes Arikayce, an inhaled liposomal amikacin for nontuberculous mycobacterial lung disease. Comparable to Pneuma on inhaled respiratory therapeutics for serious lung diseases, though Insmed is commercial-stage and Pneuma is pre-commercial.
• PARI Pharma: PARI Pharma develops nebulizer-based drug delivery platforms and eFlow technology for inhaled therapeutics in cystic fibrosis and respiratory diseases. Comparable to Pneuma's nebulizer-class aerosol technology, particularly for biologic and large-molecule formulation.

Broad incumbents

• Vectura Group: Vectura (now owned by Philip Morris) is an established inhalation device and formulation specialist licensing to pharma companies across asthma, COPD, and other respiratory indications. Comparable to Pneuma as a pharmaceutical inhaler/licensing platform, though at much greater scale and with an installed pharma partner base.
• Philip Morris International: Philip Morris International leads the reduced-risk product category with IQOS (heated tobacco) and Zyn (nicotine pouches), and now owns Vectura. Comparable to Pneuma on the nicotine harm reduction side and indirectly on inhaled therapeutics via Vectura, with vastly greater commercial scale and regulatory expertise.
• British American Tobacco: BAT operates Vuse (e-vapor), glo (heated tobacco), and Velo (modern oral nicotine), competing directly with Pneuma's reduced-risk nicotine platform. Comparable on consumer nicotine harm reduction but with global distribution and established PMTA filings.
• Altria Group: Altria markets NJOY (e-vapor) and on! (nicotine pouches), targeting the same adult-smoker harm-reduction consumer as Pneuma. Comparable on the consumer nicotine platform side, with entrenched retail relationships and regulatory know-how.
• JUUL Labs: JUUL is a major U.S. e-vapor company pursuing FDA authorization for its menthol and tobacco-flavored products. Comparable as a competitor in the reduced-harm nicotine category Pneuma is targeting, though with different aerosol-generation technology.
• GSK (GlaxoSmithKline): GSK markets leading respiratory inhaler franchises including Advair/Flovent, Trelegy, and Breo/Relvar via Ellipta and Diskus devices. Comparable as the dominant incumbent in pharmaceutical inhaled therapeutics, the very market Pneuma's Enhaler platform is targeting.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/pneumaplatform
• LinkedInlinkedin.com/company/pneuma-respiratory-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pneuma Respiratory